Precigen, Inc. Common Stock (PGEN) Stock Price

PGENStock

$6.38+82.95%52W

Market Cap$2.28B

P/E—

PEG Ratio—

Div yield—

Beta1.01

PGEN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)50.52%

Price vs S&P 500 (4W)-15.75%

VGM Score54.86

Book Value / Share (Quarterly)$0.12

P/TBV (Annual)83.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-28.86%

Cash Flow / Share (Quarterly)$-0.32

Price vs S&P 500 (YTD)40.82%

Gross Margin (TTM)90.67%

Net Profit Margin (TTM)-183.98%

EPS (TTM)$-0.52

10-Day Avg Trading Volume4.50M

EPS Excl Extra (TTM)$-0.52

Revenue Growth (5Y)-37.70%

EPS (Annual)$-0.80

ROI (Annual)-219.70%

Gross Margin (Annual)50.20%

Net Profit Margin (5Y Avg)-1576.92%

Cash / Share (Quarterly)$0.11

Revenue Growth QoQ (YoY)6322.66%

ROA (Last FY)-161.18%

Revenue Growth TTM (YoY)1875.05%

EBITD / Share (TTM)$-0.10

ROE (5Y Avg)-306.45%

Operating Margin (TTM)-46.08%

Cash Flow / Share (Annual)$-0.25

P/B Ratio52.46x

P/B Ratio (Quarterly)46.63x

Net Income / Employee (Annual)$-1,566,500

EV / Revenue (TTM)27.57x

Net Interest Coverage (TTM)-383.42x

ROA (TTM)-99.23%

EPS Incl Extra (Annual)$-0.80

Current Ratio (Annual)3.09x

Quick Ratio (Quarterly)3.76x

3-Month Avg Trading Volume5.11M

52-Week Price Return82.95%

Revenue / Employee (TTM)$535,700

Tangible BV / Share (Quarterly)$0.11

P/S Ratio (Annual)236.07x

Asset Turnover (Annual)0.06x

52-Week High$8.98

Operating Margin (5Y Avg)-1421.40%

EPS Excl Extra (Annual)$-0.80

CapEx CAGR (5Y)-23.33%

Tangible BV CAGR (5Y)58.01%

26-Week Price Return60.43%

Quick Ratio (Annual)2.74x

13-Week Price Return28.99%

Total Debt / Equity (Annual)4.46x

Current Ratio (Quarterly)4.58x

Enterprise Value$2.36B

Revenue / Share Growth (5Y)-45.06%

Asset Turnover (TTM)0.54x

Book Value / Share Growth (5Y)-30.25%

Revenue / Employee (Annual)$60,500

Inventory Turnover (Annual)21.00x

Pretax Margin (Annual)-2588.18%

Cash / Share (Annual)$0.28

3-Month Return Std Dev63.24%

Gross Margin (5Y Avg)35.84%

Net Income / Employee (TTM)$-985,700

ROE (Last FY)-1198.61%

Net Interest Coverage (Annual)-21.28x

EPS Basic Excl Extra (Annual)$-0.80

Receivables Turnover (TTM)2.37x

Total Debt / Equity (Quarterly)2.15x

EPS Incl Extra (TTM)$-0.52

Receivables Turnover (Annual)4.00x

ROI (TTM)-126.15%

P/S Ratio (TTM)26.67x

Pretax Margin (5Y Avg)-1694.33%

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$0.05

Forward P/E14.31x

Price vs S&P 500 (52W)67.42%

Year-to-Date Return52.75%

5-Day Price Return-16.64%

EPS Normalized (Annual)$-0.80

ROA (5Y Avg)-64.82%

Net Profit Margin (Annual)-2588.21%

Month-to-Date Return-25.41%

Cash Flow / Share (TTM)$-0.34

EBITD / Share (Annual)$-0.34

Operating Margin (Annual)-1141.13%

LT Debt / Equity (Annual)4.46x

ROI (5Y Avg)-101.04%

LT Debt / Equity (Quarterly)2.15x

EPS Basic Excl Extra (TTM)$-0.52

P/TBV (Quarterly)49.53x

P/B Ratio (Annual)70.73x

Inventory Turnover (TTM)21.13x

Pretax Margin (TTM)-183.98%

Book Value / Share (Annual)$0.06

Price vs S&P 500 (13W)26.30%

Beta1.01x

P/FCF (Annual)99.74x

Revenue / Share (TTM)$0.21

ROE (TTM)-498.32%

52-Week Low$3.04

vGradeF

gGradeB

mGradeB

vgmGradeC

PGEN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$0.01	$0.05	+475.09%(+$0.06)
Q1 2026	May 13, 2026	-$0.04	-$0.02	+50.00%(+$0.02)
Q4 2025	Mar 25, 2026	-$0.08	-$0.01	+88.10%(+$0.07)
Q3 2025	Nov 13, 2025	-$0.10	-$1.06	-1015.79%(-$0.97)
Q2 2025	Aug 12, 2025	-$0.08	-$0.08	+4.12%(+$0.00)

PGEN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PGENPrecigen, Inc. Common Stock	F	B	B	26.7x	1875.0%	90.7%	—	$6.38
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Precigen, Inc. Common Stock

Precigen Inc develops synthetic biology solutions and engineered gene programs for diverse applications across multiple industries. The company commercializes its technologies through exclusive strategic partnerships, generating revenue from technology access fees, royalties, and milestones. Operations are organized into two reportable segments: Biopharmaceuticals and Exemplar.

PGEN Next Earnings Report

Report dateNov 12, 2026

QuarterQ3 2026

Report timeAMC

Revenue estimate$72.31M

Also reporting on Nov 12, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

PGEN Insider Transactions

SellAug 26, 2026
KINDLER JEFFREY B
Director
Shares: 185,000Value: $1.38M
SellAug 25, 2026
TENNANT PHIL
Officer
Shares: 79,166Value: $593,745
SellAug 25, 2026
SHAH RUTUL R.
Chief Operating Officer
Shares: 50,000Value: $375,000
BuyAug 21, 2026
AGEE NANCY HOWELL
Director
Shares: 3,411Value: $24,662
SellAug 6, 2026
SHAH RUTUL R.
Chief Operating Officer
Shares: 32,739Value: $224,590

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

NGVTIngevity CorporationChemicals
ADMAADMA Biologics, Inc.Biological Products
IOSPInnospec Inc.Chemicals
ROGRogers CorporationPlastics & Resins
CLDXCelldex Therapeutics, IncIn Vitro Diagnostics
VCELVericel CorporationBiological Products
BCRXBioCryst Pharmaceuticals IncBiological Products
MTXMinerals Technologies IncIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.0

Buy

Consensus rating

52-Week Range

Low$3.04

High$8.98